研究单位：[1]Ipsen[2]Peking University Third Hospital (PUH3) Beijing,China,100000[3]Xiangya Hospital Central South University (XYHCSU) Changsha,China,410000[4]West China Hospital,Sichuan University (WCH) Chengdu,China,610000[5]The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU) Guangzhou,China,510000[6]The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU) Hangzhou,China,310000[7]Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School (NJDTH) Nanjing,China,210000[8]The First Hospital of China Medical University (CMU1H) Shenyang,China,110000[9]The Second Hospital of Hebei Medical University (HB2H) Shijiazhuang,China,050000[10]Affiliated Hospital of Wenzhou Medical University (FAHWMU) Wenzhou,China,325000[11]Tongji Hospital,Tongji Medical College,Huazhong University of Science & Technology (TJH HUST) Wuhan,China,430000[12]The First Affiliated Hospital of Zhengzhou University (FAHZZU) Zhengzhou,China,450000[13]Peking Union Medical College Hospital (PUMCH) Beijing,China,100000
研究目的：
This study aims to assess the one-year effectiveness and safety of LAN among patients with acromegaly in China in routine clinical practice. In addition, the study is designed to understand the real-world treatment patterns and outcomes of LAN among Chinese patients with acromegaly
